Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE III, Randomized, Open-Label, Comparative, Multi - Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Kidney Transplant Recipients

NCT00720265 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00720265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00720265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE III, Randomized, Open-Label, Comparative, Multi - Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Kidney Transplant Recipients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
March 31, 2008
Enrollment
135 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation